{"id":"NCT01900054","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2013-07-16","resultsPosted":"2015-12-14","lastUpdate":"2016-04-08"},"enrollment":58,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Bepotastine besilate","otherNames":["TALION 5mg tablets"]}],"arms":[{"label":"TAU-284","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.","primaryOutcome":{"measure":"Number of Patients With Adverse Events and Adverse Drug Reactions","timeFrame":"Up to Week 12","effectByArm":[{"arm":"TAU-284","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["26364765"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Otitis externa","Pharyngitis","Epistaxis"]}}